Abstracts tagged "Biologics and rheumatoid arthritis (RA)"

Abstract Number: 2832 • 2017 ACR/ARHP Annual Meeting
Finding the Optimal Treatment Strategy for Disease Activity-Guided Dose Reduction of Adalimumab and Etanercept in Rheumatoid Arthritis: A Modelling Study
D.P.G. Bos¹, L.M. Verhoef¹, C.H.M. van den Ende^1,2, F.H.J. van den Hoogen^1,2, Bruno Fautrel^3,4, M.E.J.L. Hulscher⁵, W. Kievit⁶ and A.A. Den Broeder^1,2, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud university medical centre, Nijmegen, Netherlands, ³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁴Paris VI Pierre et Marie Curie University, Paris, France, ⁵Radboud Institute for Health Sciences, IQ healthcare, Radboud university medical centre, Nijmegen, Netherlands, ⁶Department for Health Evidence, Radboud university medical centre, Nijmegen, Netherlands
Background/Purpose: Although bDMARDs are often able to control the RA, they are expensive and associated with adverse effects. Therefore, it is important to use the…
Abstract Number: 599 • 2016 ACR/ARHP Annual Meeting
Real World United States-Based Clinical Experience with Prior Biologic Use Among First Time Golimumab Intravenous and Infliximab Treated Rheumatoid Arthritis Patients
Sergio Schwartzman¹, Dennis Parenti², Shawn Black², Kehzen Tang³, Yanli Wang³ and Shelly Kafka², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4 comparator study designed to provide a real-world…
Abstract Number: 1611 • 2016 ACR/ARHP Annual Meeting
In Vitro Cellular Profiling of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti–IL-6 Receptor Monoclonal Antibody
Konstantia-Maria Chavele¹, Debbie Gardner², Matthew J Loza², Bidisha Dasgupta², Martin Sims¹, David Shealy², Juliet Reid¹ and Ravi Rao¹, ¹GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ²Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: IL-6 plays a central pathogenic role in rheumatoid arthritis (RA). IL-6 signals through a complex of transmembrane IL-6R or soluble IL-6R (sIL-6R) with gp130…
Abstract Number: 444 • 2015 ACR/ARHP Annual Meeting
TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database
Karen Salomon-Escoto¹, Nisha Kini¹, Sharina D. Person¹, J.A.P. da Silva², Gianfranco Ferraccioli³, T. W. J. Huizinga⁴, Robert B.M. Landewé⁵, RJ Moots⁶, D. van der Heijde⁷, Douglas J. Veale⁸, Ellen M. Gravallese¹ and Jonathan Kay¹, ¹University of Massachussets Medical School, Worcester, MA, ²Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, ³Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland
Background/Purpose: Biologic agents are effective treatment for rheumatoid arthritis (RA), but factors exist that may influence the prescription of these drugs in different countries. We…
Abstract Number: 1649 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
Mark C. Genovese¹, Roy Fleischmann², Yoshiya Tanaka³, Daniel E. Furst⁴, Hisashi Yamanaka⁵, Rajesh Joshi⁶, Wei Zhu⁷, Jing Shao⁸, Hideki Mashimo⁸ and Tsutomu Takeuchi⁹, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Quintiles Inc., Mumbai, India, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Tokyo, Japan, ⁹Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Olokizumab (OKZ) is a humanized anti-interleukin-6 monoclonal antibody in development for moderate-to-severe rheumatoid arthritis (RA) treatment. OKZ efficacy and safety were assessed in the…
Abstract Number: 2775 • 2015 ACR/ARHP Annual Meeting
What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?
Kaleb Michaud^1,2, Sofia Pedro² and Steven Peterson³, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To characterize which factors are associated with RA patients' preferences for biologic administration: sub-cutaneous or intravenous.Methods: Using a large US observational cohort, the National…
Abstract Number: 2529 • 2014 ACR/ARHP Annual Meeting
Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection
Kensei Tsuzaka^1,2, Yoko Akiyama² and Masayoshi Nagata¹, ¹Division of Rheumatology, Iruma Heart Hospital, Iruma, Saitama, Japan, ²Kaytee Bio, Co&Ltd, Funabashi, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of these biologics could…
Abstract Number: 996 • 2014 ACR/ARHP Annual Meeting
Memory B Cell Subtype Modulation in Patients with Rheumatoid Arthritis
Zafar Mahmood¹, Marc Schmalzing², Thomas Dörner³ and Hans-Peter Tony², ¹Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ³Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany
Background/Purpose . Memory B cells have been shown to play important roles in the pathogenesis of rheumatoid arthritis (RA). With the advent of B cell…
Abstract Number: 499 • 2014 ACR/ARHP Annual Meeting
Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic
Denis Choquette¹, Louis Coupal¹, Marie-Claude Laliberté² and Olivier Desjardins², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²AbbVie, St. Laurent, QC, Canada
Background/Purpose: Adherence and persistence to treatment are a cornerstone of treatment success in chronic diseases such as rheumatoid arthritis (RA). The purpose of this study…
Abstract Number: 466 • 2013 ACR/ARHP Annual Meeting
Biologic Monotherapy in French Rheumatoid Arthritis (RA) Patients From a Real-Life Clinical Practice Compared To Patients Treated with a Combination Therapy (Biologic + DMARD)
Philippe Dieude¹, Chantal Deslandre², Emilie Desfleurs³, Jeanne Antheaume³ and Jean-Charles Balblanc⁴, ¹Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ²Rheumatology, Cochin Hospital, Paris, France, ³Rheumatology, Roche SAS, Boulogne-Billancourt, France, ⁴Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France
Background/Purpose: Combination therapy (Biologic+non-biologic (nb)DMARDs) is the recommended therapeutic strategy in biologic-based RA treatment. However, biologics in montherapy represent around 30% of the biologic-treated patients…
Abstract Number: 435 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis
Paul Emery¹, Roy Fleischmann², Ingrid Strusberg³, Patrick Durez⁴, Peter Nash⁵, Eric Amante⁶, Melvin A. Churchill⁷, Won Park⁸, Bernardo Pons-Estel⁹, Chenglong Han¹⁰, Timothy A. Gathany¹⁰, Yiying Zhou¹¹, Stephen Xu¹² and Elizabeth C. Hsia¹², ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Instituto Reumatológico Strusberg, Cordoba, Argentina, ⁴Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁵University of Queensland, Brisbane, Australia, ⁶University of Phillipines General Hospital, Manila, Philippines, ⁷Arthritis Center of Nebraska, Lincoln, NE, ⁸Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁹Sanatorio Parque, Rosario, Argentina, ¹⁰Janssen Global Services, LLC., Malvern, PA, ¹¹Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ¹²Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Final 5yr safety and efficacy results of subcutaneous golimumab (GLM)+/-MTX evaluated in a phase 3 trial (GO-BEFORE) of MTX-naïve pts with rheumatoid arthritis (RA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].